IRIX logo

IRIDEX CORP

IRIXNASDAQ
πŸ† #4839 by market capEarnings Mar 25US Equity
$0.47β–Ό $0.05 (βˆ’9.22%)
Market closed Β· at close
πŸ””
Track IRIX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 9.2%
7dβ–Ό 30.0%
14dβ–Ό 36.4%
30dβ–Ό 47.2%
ytdβ–Ό 59.1%
1yβ–Ό 50.0%
🏦Market Cap
$8M
Small Cap
πŸ“ˆRevenue Growth (YoY)
8.2%
Slowing
πŸ“ŠGross Margin
38.5%
Healthy
πŸ’΅FCF Margin
-3.5%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.47 – $0.48
52-Week Range
$0.43 – $1.65
Volume (shares)
708
Avg Volume (shares)
β€”
Shares Outstanding
17.8M
Next Earnings
2027-03-25

Fundamentals Snapshot

Annual Revenue
$53M
Last Q Revenue
$13M
P/E Ratio
-2.3
P/S Ratio
0.2x
EPS (TTM)
$-0.19
Dividend Yield
0.00%
Dilution (1yr)
+2.2%
IRIX logo

IRIDEX CORP

IRIX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$53Mβ–² +8.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
36.7%β–Ό βˆ’8.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$3Mβ–Ό βˆ’69.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$2Mβ–Ό βˆ’69.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
17.4Mβ–² +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$667Kβ–Ό βˆ’$121K YoY
StockOtter Β· stockotter.space

About IRIDEX CORP

IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

Defense WorldΒ·3d ago

IRIDEX Q3 Earnings Call Highlights

IRIDEX (NASDAQ: IRIX) lowered its full-year revenue outlook after third-quarter sales fell short of expectations, as international distributors worked through inventory and regulatory delays and pricing pressure weighed

Seeking AlphaΒ·5d ago

IRIDEX Corporation (IRIX) Q3 2026 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q3 2026 Earnings Call Transcript

GlobeNewsWireΒ·5d ago

Iridex Reports Third Quarter 2026 Financial Results

SAN JOSE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Iridex Corporationβ€―(Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and ret

Defense WorldΒ·5d ago

Contrasting IRIDEX (NASDAQ:IRIX) and Medtronic (NYSE:MDT)

IRIDEX (NASDAQ: IRIX - Get Free Report) and Medtronic (NYSE: MDT - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their insti

GlobeNewsWireΒ·19d ago

Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026

SAN JOSE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and ret

Defense WorldΒ·Oct 7

IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Acquires 10,000 Shares

IRIDEX Corporation (NASDAQ: IRIX - Get Free Report) major shareholder Shih-Yao David Lin purchased 10,000 shares of IRIDEX stock in a transaction dated Thursday, October 16th. The shares were acquired at an average cost